CCDC6-RET Fusion is an inclusion criterion in 1 clinical trial for thyroid gland papillary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCDC6-RET Fusion and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCDC6-RET Fusion is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCDC6-RET Fusion and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCDC6-RET Fusion is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCDC6-RET Fusion and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCDC6-RET Fusion is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCDC6-RET Fusion and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

CCDC6-RET Fusion is an inclusion criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains CCDC6-RET Fusion and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [5].

CCDC6-RET Fusion is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCDC6-RET Fusion and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCDC6-RET Fusion is an inclusion criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCDC6-RET Fusion and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].